Research News and Research

RSS

TB Alliance launches three-drug combination trial for drug-sensitive and multidrug-resistant TB

In advance of the 41st Union World Conference, the Global Alliance for TB Drug Development (TB Alliance) today announced the launch of the first clinical trial to test a novel tuberculosis regimen in a new development paradigm designed to speed new treatments to patients. This novel three-drug combination shows promise to treat both drug-sensitive (DS-TB) and multidrug-resistant TB (MDR-TB), and alter the course of the TB pandemic by shortening and simplifying treatment worldwide.

8 Nov 2010

Progenics third quarter net loss increases to $17.1 million

Progenics Pharmaceuticals, Inc. today announced its results of operations for the third quarter and nine months ended September 30, 2010.

8 Nov 2010

CardioNet to acquire Biotel

CardioNet, Inc., a leading wireless medical technology company with an initial focus on the diagnosis and monitoring of cardiac arrhythmias, announced today that the Company entered into a definitive merger agreement with Biotel, Inc. to acquire all of the outstanding shares of Biotel for $11 million, or $3.84 per share, before adjustments for working capital. In connection with the merger agreement, the parties entered into a settlement agreement to dismiss the outstanding litigation between them, which will be effective as of the close of the merger.

8 Nov 2010

CPEX third quarter revenues increase 17% to $5.8 million

CPEX Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2010. For the quarter CPEX reported revenues of $5.8 million and net income of $2.4 million.

8 Nov 2010

Parascript receives $244,479.25 federal grant under Affordable Care Act

Parascript, LLC, the image analysis and pattern recognition technology provider, today announced that it was awarded a cash grant of $244,479.25 under the U.S. Government's Affordable Care Act. Under this act, the therapeutic discovery project program targets projects that show significant potential to produce new therapies, address unmet medical needs, reduce the long-term growth of health care costs or advance the goal of curing cancer within the next 30 years.

8 Nov 2010

Potential new biomarkers for very early prostate cancer

A new study presented at the National Cancer Research Institute (NCRI) conference in Liverpool next week has found potential new biomarkers for very early prostate cancer in men with no symptoms of the disease.

8 Nov 2010

Hyperuricemia associated with increased risk for hypertension

People with hyperuricemia are at an increased risk for high blood pressure, according to research presented at the Nov 2010, American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Manhattan awarded $244,279 grant under QTDP program

Manhattan Pharmaceuticals, Inc. announced today that it has been awarded $244,279 in funding under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) credit program. The Company has received this funding for its lead product candidate AST-726 for the treatment of vitamin B12 deficiency.

8 Nov 2010

GRS and CORRONA enter strategic partnership for clinical research in rheumatoid arthritis

Global Research Services, LLC (GRS), an international full-service clinical research organization (CRO), and The Consortium of Rheumatology Researchers of North America, Inc. (CORRONA), the largest independent initiative for clinical research in rheumatoid arthritis, announced today their strategic partnership to bring together Phase I-IV clinical research capabilities with the largest rheumatology patient registry in North America.

8 Nov 2010

Gentium third quarter total revenues increase to EUR 5.91 million

Gentium S.p.A. today reported financial results for the quarter ended September 30, 2010. The Company reports its financial condition and operating results using U.S. Generally Accepted Accounting Principles (GAAP). The Company's financial statements are prepared using the Euro as its functional currency.

8 Nov 2010

First Edition: November 8, 2010

Today's health policy headlines include more post-mortem reports about the health law's impact on the election.

8 Nov 2010

Spaceflights negatively impact bone health

Long-duration spaceflight may have a long-term negative impact on bone health, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Structural deformities affect typing styles of touch typists with rheumatoid arthritis

Joint damage caused by rheumatoid arthritis can lead to difficulties in typing and can force people to seek alternative—but potentially more destructive—ways of putting their fingers to the keyboard, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Apples lower risk for developing heart disease

Recent research out of the University of Michigan Health System – a premier academic medical center – has found that adding more apples and apple products to your diet may be an easy way to lower your risk for developing heart disease. More than one in three U.S. adults has one or more types of cardiovascular disease (CVD) according to the American Heart Association. Heart disease is the leading cause of death in the United States.

8 Nov 2010

U.N. Human Development Report finds significant quality of life gains among many developing countries over last 40 years, but gaps persist

"People around the globe are healthier, richer and better educated than ever before, with most developing countries registering huge gains over the last 40 years, a U.N. report [.pdf] released Thursday shows," the Canadian Press reports.

8 Nov 2010

XenoPort third quarter net loss decreases to $19.9 million

XenoPort, Inc. announced today financial results for the third quarter and nine months ended September 30, 2010. Revenues for the third quarter were $0.4 million, compared to $0.4 million for the same period in 2009. Net loss for the third quarter was $19.9 million, compared to a net loss of $24.4 million for the same period in 2009.

8 Nov 2010

Officials discuss HIV/AIDS in Caribbean during PANCAP meeting

"Despite the gains associated with antiretroviral treatments (ART) over the last decade, HIV/AIDS remains the leading cause of death among young and middle-aged adults in the Caribbean, warns a new U.N. report" that was released during the 10th Annual General Meeting of the Pan Caribbean Partnership Against HIV and AIDS (PANCAP) that concluded on Tuesday, Inter Press Service reports (Richards, 11/3).

8 Nov 2010